Technical Areas in Stem Cell Patenting and Ownership

Technical areas in Stem cell Patenting and ownership Stem cells in fast emerging scenario act as the best biotechnological application in both therapeutic and cellular therapeutics. With recent advancement in medical and genetic manipulations, its profound applicability in novel therapeutics have put a question its efficiency as a cell based product and of intellectual property rights and technology transfer. In recent times, academic Institutes and Corporations account to over 85% of both published patent applications and granted stem cell patents where corporation are in the priority list. (www.ipo.gov.uk/informatic-stemcells.pdf or report from UK IPO Patent Informatics Team, June 2012). Analysis of published patent applications suggest recent research to be mainly focused on mesenchymal stem cells, embryonic stem cells and artificially induced pluripotent cells where, ESCs, hematopoietic stem cells (HSCs) and neural stem cells (NSCs) appear to be successfully used respectively in cardiovascular disease, diabetes, neurological diseas e and tissue and organ stem cell therapy. Stem cell patenting activity is mainly concentrated in the United States (21%), the World Intellectual Property Organization (WIPO) (PCT) (19%), EPO (14%), Australia (12%), Canada and Japan (7%), Germany (3%), and China and the United Kingdom (2%). In the year 2012, PCT, EPO and Republic Korea were the main countries with most IPC where Shin, Dong Wook had 7 patents on their name. In view of currentShow MoreRelatedCompetitive Advantage: Creating and Sustaining Superior Performance65536 Words   |  263 PagesThe bigger question are: 1. Why do firms outperform one another? 2. What is the process is by which firms discover unique strategies, put them in place, and modify them when conditions change. The failure of many firms strategy stems from an inability to translate a broad competitive strategy in to the specific action steps required to gain competitive advantage. The objective of this book is to build a bridge between strategy formulation and implementation rather than treatingRead MoreGsk Annual Report 2010135604 Words   |  543 PagesGrowth of Horlicks in India in 2010. 10 10 new compounds and vaccines starting phase III clinical trials since the start of 2010. 14% We are committed to improving returns in RD, aiming to increase our estimated return on investment in this area to 14%. c.1bn Units of Lucozade, Ribena and Horlicks manufactured in the UK every year. 2 New Consumer Healthcare Research and Innovation centres opened in China and India. Vaccines Emerging markets 1.4bn Doses of our vaccines suppliedRead MoreGeneral Electric60506 Words   |  243 Pagesperformance cannot reach full potential unless each area of the organization does its part and contributes directly to the desired companywide outcomes and results. This means setting performance targets for each organization unit that support, rather than conflict with or negate, the achievement of companywide strategic and financial objectives. The ideal situation is a team effort in which each organizational unit strives to produce results in its area of responsibility that contributes to the achievementRead MoreDamodaran Book on Investment Valuation, 2nd Edition398423 Words   |  1594 Pageswhich implies that the price paid for any asset should reflect the cashflows that it is expected to generate. The models of valuation described in this book attempt to relate value to the level and expected growth in these cashflows. There are many areas in valuation where there is room for disagreement, inc luding how to estimate true value and how long it will take for prices to adjust to true value. But there is one point on which there can be no disagreement. Asset prices cannot be justified by